--- title: 'Vice President, Clinical Development, Danicamtiv (DANI) at Kardigan' canonical: 'https://feeny.ai/job/vice-president-clinical-development-danicamtiv-dani-kardigan-princeton-new-yvmee393a5pb' type: 'job' last_seen: '2026-09-12' --- # Vice President, Clinical Development, Danicamtiv (DANI) at Kardigan - **Company:** Kardigan - **Location:** Princeton New Jersey United States South San Francisco California, United States - **Compensation:** $340k–$416k - **Posted:** 2026-06-24 - **Last confirmed live:** 2026-09-12 - **Apply:** https://job-boards.greenhouse.io/kardigan/jobs/5204838008 ## Job description ## About Us Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world. It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve. Led by Tassos Gianakakos, Jay Edelberg, M.D., Ph.D., and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020. We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients. At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. Driven by patients and their families, we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in being authentic—leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an eagerness to learn, we encourage the highest levels of curiosity and are open to changing our minds. We are committed to winning as a team with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to enable the impossible because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries. These values are the foundation of our work, empowering us to make a real difference, every day. The VP, Clinical Development will have direct responsibility as Clinical Lead accountable for clinical development strategy and execution across one or more programs. The successful candidate will be a highly credible physician leader, a strong people manager, and a trusted thought partner to the program GPH, other VP-CDLs, the CMO, the CEO, and Executive Committee members. ## Key Responsibilities Danicamtiv Program – Clinical Lead - Serve as the Clinical Lead for the Danicamtiv program, with end-to-end accountability for clinical strategy and execution, including protocol development and approval and regulatory interactions. - Lead the Danicamtiv Clinical Strategy Team (CST) with cross-functional leadership in development and execution of the Danicamtiv clinical development plan. - Own clinical development plans, and protocol design, with critical input for indication selection and target product profile (TPP) development for Danicamtiv. - Lead clinical decision-making based on emerging data, benefit–risk assessments and evolving regulatory interactions and expectations. - Act as the primary clinical development point of contact for regulatory interactions, investigators, and key opinion leaders related to the Danicamtiv program. - Partner closely with colleagues from Clinical Operations, Biometrics, Regulatory, and Medical Affairs to ensure seamless oversight and execution of clinical trials across the Danicamtiv program. Executive & External Engagement - Act as a senior clinical representative for discussions with the Kardigan Executive Committee, as needed. - Present clinical strategy, study progress, and risks to internal leadership and, when needed, to the Kardigan Executive Committee and Board of Directors. - Represent the Kardigan clinical development function externally at scientific meetings, advisory boards, and interactions with Key Opinion Leaders, related to the  Danicamtiv programs and potentially for other drug programs, as well. ## Qualifications - MD (or equivalent medical degree); board certification and clinical practice experience in cardiology strongly preferred. - 15+ years of experience in clinical development within biotechnology and/or pharmaceutical companies– experience in cardiomyopathy and/or heart failure drug development and deep knowledge of cardiomyopathy and heart failure clinical care delivery, clinical research landscape, scientific literature, competitive drug development environment, and regulatory pathways strongly preferred. - Demonstrated experience serving as clinical lead for a major drug program or asset, ideally through key late-stage development milestones. - Strong understanding of cardiovascular clinical trial designs, endpoints in cardiovascular trials, and regulatory strategies for cardiovascular drug development. - Well-developed relationships with key external experts in the cardiomyopathy/heart failure field and demonstrated track record of overseeing external research collaborations for cardiomyopathy/heart failure topics. - Experience with genetic screening initiatives for clinical research and clinical care delivery purposes desired. - Proven ability to influence and lead cross-functional teams. - Experience in late-stage development and/or regulatory submissions. - Prior experience managing or mentoring other MDs. - Experience in a high-growth or emerging biotech environment. - Track record of effective partnership with a CMO or senior medical leadership. Leadership Characteristics - Highly credible clinical development leader with strong clinical judgment. - Strategic thinker who balances rigor with speed and pragmatism. - Strong collaborator and people leader with extensive experience leading and building teams. - Comfortable operating in ambiguity and helping design future-state organizations. Exact Compensation may vary based on skills, experience and location. Pay range $340,000—$416,000 USD ## About Kardigan ## Company Overview - **One-liner**: Kardigan is a publicly traded biopharmaceutical company developing targeted cardiovascular therapies with the aim of transforming treatment from symptom management toward functional cures. - **Entity Type**: Public (ticker not available from provided sources; IPO closed as per company announcement) - **Headquarters**: South San Francisco, California, United States (with additional offices in Princeton, New Jersey and Chicago, Illinois) - **Founded**: Year not specified in available sources - **Founders**: Tassos Gianakakos (Co-Founder, CEO & Chair), Dr. Jay Edelberg (Co-Founder & Chief Medical Officer), Dr. Bob McDowell (Co-Founder & Scientific Adviser), Brianne Puglisi (Co-Founder) ## Core Business - **Primary industry**: Biopharmaceuticals – cardiovascular drug discovery and development - **Target customers**: B2B / B2G – healthcare providers, hospitals, payers, and patients; the company develops prescription medicines for serious cardiovascular conditions - **Mission or purpose statement**: “To make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.” ([kardigan.bio](https://www.kardigan.bio/)) ## Products & Services - **Tonlamarsen**: A Phase 2/3 candidate for acute severe hypertension (ASH) and uncontrolled hypertension. Positive Phase 2 data presented as a late-breaker at ACC.26 and simultaneously published in JACC. ([kardigan.bio](https://www.kardigan.bio/)) - **Danicamtiv**: A Phase 3 candidate for genetic dilated cardiomyopathy (DCM), targeting the underlying inherited cardiac muscle disease. ([kardigan.bio](https://www.kardigan.bio/)) - **Calcific Aortic Valve Stenosis (CAVS) Program**: A late-stage clinical program addressing calcium deposition that stiffens the aortic valve. ([kardigan.bio](https://www.kardigan.bio/)) - **Prolaio Subsidiary**: An AI and real‑world data platform integrated into Kardigan to generate insights, inform clinical trial design, and reduce time/cost of drug development. ([kardigan.bio](https://www.kardigan.bio/about-us/)) - **Cardiac Intelligence Platform**: A discovery and translational research engine that uses real‑world patient data, AI, and deep cardiovascular expertise to identify disease drivers and design targeted therapies. ([kardigan.bio](https://www.kardigan.bio/)) ## Market Standing - **Valuation/Market Cap**: Not disclosed in provided sources - **Key Metric**: Public company (IPO closed); annual revenue not disclosed - **Notable Investors/Partners**: Not explicitly listed in provided sources; company built on the team’s track record from MyoKardia (acquired by Bristol Myers Squibb for $13.1B in 2020) - **Growth Signals**: - Positive Phase 2 pivotal data for Tonlamarsen in hypertension, presented at ACC.26 and published in JACC - Three late‑stage clinical programs (CAVS, ASH, DCM) running in parallel - Active job postings across 210+ roles in clinical operations, data science, manufacturing, and corporate strategy, indicating scaling ([job-boards.greenhouse.io/kardigan](http://job-boards.greenhouse.io/kardigan)) - Integration of Prolaio’s AI platform to accelerate R&D ## Competitive Advantages - **Leadership expertise**: CEO Tassos Gianakakos previously scaled MyoKardia from startup to a $13.1B acquisition; the team includes veterans from MyoKardia, Sanofi, BMS, and Merck. - **Parallel pipeline strategy**: Multiple late‑stage programs targeting distinct cardiovascular diseases (valve, hypertension, cardiomyopathy) de‑risks development and creates data synergies. - **Cardiac Intelligence platform**: Proprietary combination of real‑world data, AI, and deep biological insight to move beyond symptom management toward modifying underlying disease. - **Focus on functional cures**: Each program aims to alter the course of disease rather than merely treat symptoms, creating potential for breakthrough efficacy. ## Strategic Focus - **Advance late‑stage clinical trials**: Continue Phase 2/3 studies for Tonlamarsen, Danicamtiv, and CAVS while preparing for potential regulatory submissions. - **Expand platform capabilities**: Leverage Prolaio’s AI and real‑world evidence to design smarter, faster trials and discover new drug targets. - **Build commercial infrastructure**: Growing corporate strategy, medical affairs, and manufacturing teams in South San Francisco, Princeton, and Chicago signals preparation for launch. ## Why Work Here - **Culture**: “Everything we do starts with patients – and it’s powered by people.” Emphasis on collaboration, purpose‑driven work, and achieving the impossible together. Mission‑oriented environment focused on curing cardiovascular disease. ([kardigan.bio](https://www.kardigan.bio/job-openings/)) - **Work model**: Roles are listed for South San Francisco, Princeton, NJ, and Chicago, IL; likely on‑site/hybrid given the lab and clinical development nature. Not purely remote. - **Benefits**: - Competitive salaries and annual bonus program - Comprehensive medical, dental, and vision coverage - 401(k) plan, life and disability insurance - Flexible spending and health savings accounts - Commuter benefits, cellphone allowance - Paid holidays and time off - Employee assistance program ([kardigan.bio](https://www.kardigan.bio/job-openings/)) - **Engineering & data science culture**: Active recruitment for data analytics, AI, and clinical data science roles; Executive Director of Data, AI & Collaboration Services is an open position, reflecting a strong tech‑driven R&D approach. ## Sources 1. [kardigan.bio](https://www.kardigan.bio/) – Company homepage and pipeline descriptions 2. [kardigan.bio/about-us](https://www.kardigan.bio/about-us/) – About Us, mission, and Prolaio integration 3. [kardigan.bio/job-openings](https://www.kardigan.bio/job-openings/) – Careers page with benefits and open roles 4. [kardigan.bio/leadership](https://www.kardigan.bio/leadership/) – Leadership team and co‑founder backgrounds 5. [job-boards.greenhouse.io/kardigan](http://job-boards.greenhouse.io/kardigan) – Detailed job listings (32+ postings) ## Other roles at Kardigan - [Senior Director, Product Strategy](https://feeny.ai/job/senior-director-product-strategy-kardigan-princeton-new-jersey-zrx68wcapady) — Princeton New Jersey, United States - [Sr. Director, Clinical Trial Optimization](https://feeny.ai/job/sr-director-clinical-trial-optimization-kardigan-princeton-new-jersey-05t1jx6jawfw) — Princeton New Jersey, United States - [Director, Demand/Supply Planning](https://feeny.ai/job/director-demand-supply-planning-kardigan-south-san-francisco-jcz16k67hq5r) — South San Francisco, CA - [Scientist, Drug Metabolism and Pharmacokinetics (DMPK)](https://feeny.ai/job/scientist-drug-metabolism-and-pharmacokinetics-dmpk-kardigan-south-san-x3c0x3gmm3r7) — South San Francisco California, United States - [Sr. Executive Assistant - Contract to Hire](https://feeny.ai/job/sr-executive-assistant-contract-to-hire-kardigan-south-san-francisco-s62w5nabntfw) — South San Francisco, CA - [Director, Clinical Trial Liaison West](https://feeny.ai/job/director-clinical-trial-liaison-west-kardigan-united-states-t8xmqj8mg16m) — United States - [Senior Director, CMC Regulatory](https://feeny.ai/job/senior-director-cmc-regulatory-kardigan-princeton-new-jersey-74vt09gwp1cj) — Princeton New Jersey, United States - [Senior Director, CMC Regulatory](https://feeny.ai/job/senior-director-cmc-regulatory-kardigan-south-san-francisco-california-xjzf831d0r9n) — South San Francisco California, United States - [Head of Medical Affairs](https://feeny.ai/job/head-of-medical-affairs-kardigan-princeton-rq45s28mr31y) — Princeton, NJ - [Director, Product Quality Lead](https://feeny.ai/job/director-product-quality-lead-kardigan-south-san-francisco-california-united-ft71es75vxe9) — South San Francisco California United States Princeton New Jersey, United States